Shanghai Pioneer Holding Ltd (HK:1345)
:1345
Top Page
Shanghai Pioneer Holding Ltd
(1345)
Select Model
Select Model
Rating:74Outperform
Price Target:
HK$2.50
â–²(11.11% Upside)
Action:UpgradedDate:10/29/25
The stock's overall score is driven by strong financial performance and positive technical indicators. The stable financial health and attractive dividend yield are significant strengths, while the moderate valuation suggests room for growth. The absence of earnings call and corporate events data did not impact the score.
Positive Factors
Low leverage / robust balance sheet
A low debt-to-equity ratio and stable capital structure reduce refinancing and liquidity risk, giving management flexibility to fund R&D, M&A or capital expenditures. This financial strength supports durable operations and resilience through sector cycles over the next 2–6 months.
Negative Factors
Declining revenue trend
A near-term revenue decline of ~17.6% signals material demand or market-share challenges. Persisting revenue contraction reduces scale benefits, pressures margins and free cash flow, and may limit the firm's ability to invest in growth or absorb regulatory and competitive headwinds over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / robust balance sheet
A low debt-to-equity ratio and stable capital structure reduce refinancing and liquidity risk, giving management flexibility to fund R&D, M&A or capital expenditures. This financial strength supports durable operations and resilience through sector cycles over the next 2–6 months.
Read all positive factors
Shanghai Pioneer Holding Ltd (1345) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.75B
Dividend Yield5.26%
Average Volume (3M)54.17K
Price to Earnings (P/E)21.9
Beta (1Y)0.14
Revenue Growth-17.61%
EPS Growth-35.76%
CountryHK
Employees335
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.06
Shares Outstanding1,257,447,000
10 Day Avg. Volume73,600
30 Day Avg. Volume54,166
Financial Highlights & Ratios
PEG Ratio2.03
Price to Book (P/B)2.31
Price to Sales (P/S)1.68
P/FCF Ratio12.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Shanghai Pioneer Holding Ltd Business Overview & Revenue Model
Company Description
China Pioneer Pharma Holdings Limited, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People's Republic of China. It has a portfolio of pharmaceutical products, such as opht...
How the Company Makes Money
Shanghai Pioneer Holding Ltd generates revenue through multiple streams, primarily by manufacturing and selling industrial products, which accounts for a significant portion of its income. The company also earns money through its logistics service...
Shanghai Pioneer Holding Ltd Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.36B | 1.53B | 1.57B | 1.56B | 1.43B | 1.33B |
| Gross Profit | 635.74M | 683.21M | 668.24M | 780.47M | 772.03M | 607.97M |
| EBITDA | 197.81M | 215.27M | 201.88M | 245.38M | 199.96M | 104.79M |
| Net Income | 104.40M | 151.62M | 145.72M | 235.30M | 142.63M | 52.45M |
Balance Sheet | ||||||
| Total Assets | 1.41B | 1.46B | 1.53B | 1.57B | 1.33B | 1.43B |
| Cash, Cash Equivalents and Short-Term Investments | 195.12M | 103.57M | 124.43M | 289.01M | 402.08M | 254.61M |
| Total Debt | 134.85M | 75.22M | 74.02M | 37.59M | 14.05M | 15.10M |
| Total Liabilities | 323.03M | 342.52M | 513.14M | 549.18M | 417.49M | 516.73M |
| Stockholders Equity | 1.08B | 1.11B | 1.01B | 1.01B | 907.97M | 909.43M |
Cash Flow | ||||||
| Free Cash Flow | 172.15M | 208.01M | -163.24M | 19.02M | 225.43M | 39.37M |
| Operating Cash Flow | 192.84M | 214.83M | -118.69M | 93.30M | 242.06M | 74.24M |
| Investing Cash Flow | -91.02M | -99.76M | 69.51M | -12.99M | 8.39M | 23.93M |
| Financing Cash Flow | -73.24M | -125.92M | -50.56M | -91.03M | -140.28M | -253.04M |
Shanghai Pioneer Holding Ltd Technical Analysis
Negative
2.25
Price Trends
2.29
Negative
2.22
Negative
2.12
Positive
Market Momentum
>-0.01
Positive
38.69
Neutral
72.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1345, the sentiment is Negative. The current price of 2.25 is below the 20-day moving average (MA) of 2.29, below the 50-day MA of 2.29, and above the 200-day MA of 2.12, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.69 is Neutral, neither overbought nor oversold. The STOCH value of 72.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1345.
Shanghai Pioneer Holding Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$2.75B | 21.93 | 9.52% | 5.26% | -17.61% | -35.76% | |
69 Neutral | HK$2.36B | 5.13 | 12.91% | 15.40% | -1.88% | 17.57% | |
68 Neutral | HK$2.00B | 4.06 | 7.38% | 9.29% | -3.19% | -20.30% | |
66 Neutral | HK$1.73B | 7.90 | 6.34% | 5.16% | 2.89% | -68.83% | |
56 Neutral | HK$291.12M | 24.91 | 1.78% | 5.87% | -10.78% | -82.81% | |
53 Neutral | HK$254.79M | 15.20 | 2.98% | 28.00% | -1.68% | -111.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1345
Shanghai Pioneer Holding Ltd
2.29
0.18
8.53%
HK:1110
Kingworld Medicines Group Ltd.
0.48
0.06
14.29%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.84
0.46
19.33%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.15
0.15
15.00%
HK:2633
Jacobson Pharma Corporation Limited
1.24
0.22
21.57%
HK:3390
Tycoon Group Holdings Limited
0.29
-3.18
-91.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.